



270

PATENT
ATTORNEY DOCKET NO.: 056291-5180

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:)
)
Nicholas J. NEWCOMBE et al.)
)
Application No.: 10/507,163) Group Art Unit: 1615
)
Filed: September 9, 2004) Examiner: Unassigned
)
FOR: PYRIMIDINE COMPOUNDS)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop** ____
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: March 31, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

These references were cited in an International Search Report dated June 26, 2003 in the corresponding PCT application from which the above-identified application is a U.S. national stage application. A copy of that International Search Report was filed in the above-identified application on September 9, 2004. The Notice of Acceptance in the above-identified application did not confirm receipt of the references cited in the International Search Report.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.


Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5180 and proceed to consider this IDS.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: March 31, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

Client Ref.

056291-5180

100673-1P US

Applicants: Newcombe et al.

Appln. No.: 10/507,163

Filing Date: September 9, 2004

Examiner: Unassigned

Group Art Unit: 1615

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: March 31, 2005

Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
	GR	02/20512 A	03/2002	WIPO	Breault et al.				
	HR	01/14375 A	03/2001	WIPO	Beattie et al.				
	IR								
	JR								
	KR								
	LR								
	MR								
	NR								
	OR								
	PR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	QR								
	RR								
	SR								
	TR								
	UR								
	VR								
	WR								
	XR								

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

